Mayer Brown - James R. Ferguson

Home   |   Contact   |   Pro Bono   |   Diversity    

 

Printer Friendly Version

James R. Ferguson 
Partner

Experience 

James R. Ferguson has a practice that emphasizes intellectual property, complex commercial and white-collar criminal litigation. He has served as lead trial counsel for major corporations in patent, trademark, trade secret, and Lanham Act litigation in the pharmaceutical, medical device, insurance, financial, computer and chemical industries.

A former federal prosecutor, Jim has also served as lead trial counsel for corporations, partnerships, and other entities in a broad range of commercial and white-collar criminal litigation, including antitrust, securities, environmental and tax cases. He has tried more than 50 trials to verdict and argued more than 40 appeals in federal and state appellate courts. He has also conducted numerous corporate internal investigations.

Jim has been called a “phenomenal” lawyer who “earned his spurs as a 'high energy' operator whose practice includes IP and white-collar criminal defense” (Chambers USA). Jim is a Fellow of the American College of Trial Lawyers, and he is listed in Chambers’ America’s Leading Lawyers for Business (Litigation), The Best Lawyers in America (Bet-the-Company, Commercial and White Collar Criminal Litigation), Legal 500 and Leading Lawyers Network.

Notable Engagements 

  • Lead trial counsel in the successful defense of a national partnership charged with infringing a federally-registered trademark.  Featured in both IP 360 (July 24, 2009) and BNA Patent and Trademark Reporter (July 31, 2009), the case is the first reported decision in which the defendant obtained both a preliminary and a permanent injunction against the owner of a federally registered mark. Tuccillo v. Geisha NYC, LLC, 635 F.Supp.2d 227 (E.D.N.Y. 2009).
  • Lead trial counsel for Abbott Laboratories in winning summary judgment in an appeal to the DC district court from a PTO interference proceeding involving a patent covering a novel protein.  Featured in IP 360 (Sept. 16, 2008), the case is the first reported decision addressing the issue of whether a partial amino acid sequence provides sufficient written description for a novel protein.  Abbott GmbH & Co. KG v. Yeda Research & Dev. Co., Ltd., 576 F.Supp.2d 44 (D.D.C. 2008).
  • Lead trial counsel for two national financial institutions charged in two separate cases with infringing business methods patents covering methods of selecting stocks for institutional investment funds.  In both cases, the plaintiff voluntarily dismissed its complaint with prejudice following our disclosure of invalidating prior art and non-infringement positions.  First Trust Portfolios L.P. v. Jackson Nat’l Life Ins. Co., et al., Case No. 08 CV 4853 (N.D. Ill. 2009); First Trust Portfolios L.P. v. JNL Variable Fund LLC, et al., Case No. 07 CV 3011 (N.D. Ill. 2008).
  • Lead trial counsel for McDonald’s Corporation in the successful defense against a charge of infringing a business methods patent covering a computerized method involving pre-paid gift cards.  The plaintiff agreed to an extremely favorable settlement following our disclosure of prior art and non-infringement positions.  Card Activation Technologies v. McDonald’s Corp., Case No. 06 CV 5578 (N.D. Ill. 2007).
  • Lead trial counsel for Solvey Pharmaceuticals subsidiaries in two consolidated patent cases brought under the Hatch-Waxman Act that resulted in a consent judgment of patent validity and infringement. The consolidated case involved patent challenges by two different ANDA filers to the first transdermally-administered hormone ever approved by the FDA, with annual revenues in excess of $300 million.  Unimed Pharmaceuticals, Inc. v. Watson Pharmaceuticals, Inc. and Paddock Laboratories, Case No. 05-CV-2503 (N.D. Ga. 2006).
  • Lead trial counsel for a California computer company in winning a jury verdict of no liability following a four-week jury trial against a plaintiff seeking more than $40 million in damages.  The jury found no liability based on our affirmative defenses of ratification and in pari delicto  Williams Electronic Games, Inc. v. Milgray Electronics, et al., Case No. 97 C 3434 (N.D. Ill. 2004).
  • Defended Abbott Laboratories as lead trial and appellate counsel in a patent infringement action that resulted in summary judgment of patent invalidity, which was affirmed by the Federal Circuit. PTS Labs LLC v. Abbott Laboratories, 25 Fed.Appx. 1992 (2003).
  • Lead trial and appellate counsel for a major branded pharmaceutical company in a patent case brought under the Hatch-Waxman Act that resulted in a Federal Circuit victory and a favorable settlement. Knoll Pharmaceutical Co. v. Teva Pharmaceuticals, 367 F.3d 1381 (Fed. Cir. 2004).  The Federal Circuit’s decision upheld the admissibility of three scientific studies commissioned after the filing of the litigation to show the synergistic effect of the patented combination.
  • Lead trial counsel for Abbott Laboratories in an appeal to the district court from a PTO interference proceeding involving a patent for covering a method for amplifying target nucleic acid through ligase chain reaction (settled favorably). Abbott Laboratories v. City of Hope, (N.D. Ill. 2002).
  • Lead trial counsel for a Fortune 150 company in two declaratory judgment actions challenging the validity of a patent covering textile manufacturing methods (settled favorably). Fruit of the Loom v. Sara Lee Corp.; Russell Corp. v. Sara Lee Corp. (N.D. Ill. 2000).
  • Lead trial counsel for Abbott Laboratories in winning a permanent injunction against a competitor that had made misleading comparative statements about the client’s product. Abbott Laboratories v. PTS Labs, (N.D. Ill. 2000).
  • Represented Abbott Laboratories in winning a permanent injunction against a competitor that had made misleading statements about the FDA status of the client’s drug. Abbott Laboratories v. Watson Pharmaceuticals, Inc., (N.D. Ill. 2001).
  • Lead trial counsel for a subsidiary of Solvey Pharmaceuticals in defeating an attempt to enjoin the company from terminating its co-marketing and co-promotion agreements with another company. Boehringer Ingelheim v. Solvay Pharmaceuticals, (C.D. Ohio 2001).
  • Lead trial counsel for a Fortune 500 company in winning a jury verdict of acquittal following a four-week jury trial in a criminal case involving allegations of price-fixing and bid-rigging.
  • Lead trial counsel for a corporate executive in winning a jury verdict of acquittal following a two-week criminal trial involving alleged violations of state and federal environmental laws.
  • Lead trial counsel for a hospital corporation in winning a jury verdict of liability following a two-week trial in a case involving violations of a non-compete agreement.
  • Lead appellate counsel for a former Assistant US Attorney in winning an en banc Seventh Circuit decision overturning a panel opinion critical of the prosecutor.
  • Lead appellate counsel for an Illinois attorney in winning a major Illinois Supreme Court decision in a defamation action involving a lawyer’s ethical obligation to report misconduct by other attorneys. Skolnick v. Altheimer & Gray, 191 Ill 2nd. 214 (2000).

Education 

Northwestern University School of Law, JD; Articles Editor, Northwestern University Law Review • Indiana University, BA; Phi Beta Kappa

Admitted

  • US Court of Appeals for the Federal Circuit
  • US Tax Court
  • US Court of Appeals, Second Circuit
  • US District Court, District of Connecticut
  • US District Court, Northern District of Illinois, including Trial Bar
  • US Court of Appeals, Seventh Circuit
  • Illinois


 

James R. Ferguson

James R. Ferguson
Partner
jferguson@mayerbrown.com
Chicago
Ph: +1 312 701 7282
Fax: +1 312 706 8421
Download vCard
"...'phenomenal'...earned his spurs as a 'high energy' operator whose practice includes IP and white-collar criminal defense."
Chambers USA
 
Publications
Seminars and Presentations
Professional Activities